Hanmi to co-market GSK’s three medicines
Published: 2009-05-13 06:59:00
Updated: 2009-05-13 06:59:00
Hanmi Pharm and GlaxoSmithKline announced on May 8 that the two companies have signed a strategic alliance agreement to co-promote Seretide (fluticasone + salmetelol), Avamys (fluticasone furoate) and Flixonase (fluticasone) in Korea.
Underscoring the important synergy created by this partners...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
